Search

Prenatal screening of fetal aneuploidy is a continuously and rapidly evolving area of research; there have been tremendous advancements over the past decades in prenatal screening for aneuploidy, especially during the first trimester. As there is extensive evidence that effective screening for major chromosomal abnormalities can be provided in the first trimester of pregnancy, recently we have changed our practice; the prenatal screening of fetal chromosomal aberrations has been moved and pointed to the first trimester. Besides the nuchal translucency, which is one of the most known ultrasonographic markers, there are other markers, which can be examined during the first trimester of pregnancy. To maximize the quality of sonography, increase the screening sensitivity, and decrease the range of false-positive rate, all of the first-trimester ultrasound markers have well-established criteria for the measurement. With the use of high standards of scanning, the early recognition of sonographic markers of chromosomal aberrations can be helpful in forward prenatal diagnosis. On the contrary, the early diagnosis makes the termination of the pregnancy possible with fewer complications, and there is time for planning of further follow-up and interventions. How to cite this article Belics Z, Papp Z. Ultrasound Markers of Aneuploidy in the First Trimester. Donald School J Ultrasound Obstet Gynecol 2017;11(1):20-28.

Rationale and Objectives: MR-guided Focused Ultrasound Surgery (MRgFUS) is an evolving thermoablative technique for treatment of benign and malignant soft tissue tumors. The feasibility and effectiveness of this non-invasive method has been tested by several investigators by treating uterine fibroid. The aim of the present study was to evaluate early and mid-term efficacy of MRgFUS treatment using MR imaging follow-ups. Materials and Methods: 38 patients with uterine fibroids were enrolled and treated by MRgFUS in a single center. MRI follow-up exams were performed 3 and 6 months after the procedure. Total fibroid volumes (FV) and non-perfused volumes (NPV) were compared and evaluated over time. Results: There was a significant reduction of FV at 3- and 6-month follow-ups (10±19%, p=0.022 and 19±29%, pConclusion: This study suggests that MRgFUS can effectively coagulate uterine fibroid tissue. Smaller UFs can be most effectively treated within reasonable time with the used equipment.